von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R., Lyon, E., & Ward, B. E. (2008) · Genetics in Medicine · doi:10.1097/gim.0b013e31816b5cae · Cited by 832
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
Self-citationVon Hippel-Lindau Disease: Current Challenges and Future Prospects
Gläsker, S., Vergauwen, E., Koch, C. A., Kutikov, A., & Vortmeyer, A. O. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s190753 · Cited by 99
Research works printed but not linked: 62
- Bausch, 2013, Renal cancer in von Hippel-Lindau disease and related syndromes, Nat. Rev. Nephrol., 9, 529, 10.1038/nrneph.2013.144 · DOI
- Bertelsen, 2010, 153, 35
- Binderup, 2013, Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark, Dan Med J, 60, B4763
- Binderup, 2015, New von Hippel-Lindau manifestations develop at the same or decreased rates in pregnancy, Neurology, 85, 1500, 10.1212/WNL.0000000000002064 · doi:10.1212/wnl.0000000000002064
- Binderup, 2015, Risk of new tumors in von Hippel-Lindau patients depends on age and genotype, Genet. Med., 18, 89, 10.1038/gim.2015.44 · DOI
- Binderup, 2016, Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark, Eur. J. Hum. Genet., 25, 301, 10.1038/ejhg.2016.173 · DOI
- Binderup, 2017, Survival and causes of death in patients with von Hippel-Lindau disease, J. Med. Genet., 54, 11, 10.1136/jmedgenet-2016-104058 · DOI · Paper page
- Binderup, 2018, von Hippel-Lindau disease: diagnosis and factors influencing disease outcome, Dan Med J, 65
- Blansfield, 2007, Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs), Surgery, 142, 814, 10.1016/j.surg.2007.09.012 · doi:10.1016/j.surg.2007.09.012
- Bui, 2021, Scanxiety: a scoping review about scan-associated anxiety, BMJ Open, 11, 10.1136/bmjopen-2020-043215 · DOI
- Cascon, 2007, Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients, Hum. Mutat., 28, 613, 10.1002/humu.20496 · DOI
- Chahoud, 2020, Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease, World J. Urol., 39, 2409, 10.1007/s00345-020-03441-3 · DOI
- Cybulski, 2002, Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene, J. Med. Genet., 39, E38, 10.1136/jmg.39.7.e38 · DOI
- Decker, 2014, Clinical utility gene card for: von Hippel-Lindau (VHL), Eur. J. Hum. Genet., 22, 10.1038/ejhg.2013.180 · DOI
- Evans, 2010, Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service, Am. J. Med. Genet., 152A, 327, 10.1002/ajmg.a.33139 · DOI · Paper page
- Falconi, 2016, ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors, Neuroendocrinology, 103, 153, 10.1159/000443171 · DOI · Paper page
- Feletti, 2016, Von Hippel-Lindau disease: an evaluation of natural history and functional disability, Neuro Oncol., 18, 1011, 10.1093/neuonc/nov313 · DOI
- Franke, 2009, Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype-phenotype correlations in VHL patients, Hum. Mutat., 30, 776, 10.1002/humu.20948 · DOI
- Frantzen, 2012, Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease, Neurology, 79, 793, 10.1212/WNL.0b013e3182661f3c · doi:10.1212/wnl.0b013e3182661f3c
- Fraser, 2007, Study comparing two types of screening provision for people with von Hippel-Lindau disease, Fam. Cancer, 6, 103, 10.1007/s10689-006-9111-y · doi:10.1007/s10689-006-9111-y
- Glasker, 1999, The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system, J. Neurol. Neurosurg. Psychiatry, 67, 758, 10.1136/jnnp.67.6.758 · DOI
- Gonzalez-Rodriguez, 2019, Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial, BMJ Open Ophthalmol., 4, 10.1136/bmjophth-2018-000203 · DOI
- Gossage, 2015, VHL, the story of a tumour suppressor gene, Nat. Rev. Cancer, 15, 55, 10.1038/nrc3844 · DOI · Paper page
- Hammel, 2000, Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau, Gastroenterology, 119, 1087, 10.1053/gast.2000.18143 · DOI · Paper page
- Hes, 2005, Von hippel-lindau disease, Hered. Cancer Clin. Pract., 3, 171, 10.1186/1897-4287-3-4-171 · DOI
- Hes, 2007, Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification, Clin. Genet., 72, 122, 10.1111/j.1399-0004.2007.00827.x · DOI
- Hes, 2001, Clinical management of von hippel-lindau (VHL) disease, Neth. J. Med., 59, 225, 10.1016/S0300-2977(01)00165-6 · doi:10.1016/s0300-2977(01)00165-6
- Huntoon, 2021, Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease: a consensus statement, J. Neurosurg., 1
- Jasim, 2020, Metastatic pheochromocytoma and paraganglioma: management of endocrine manifestations, surgery and ablative procedures, and systemic therapies, Best Pract. Res. Clin. Endocrinol. Metabol., 34, 10.1016/j.beem.2019.101354 · DOI
- Kasparian, 2015, Through the looking glass: an exploratory study of the lived experiences and unmet needs of families affected by Von Hippel-Lindau disease, Eur. J. Hum. Genet., 23, 34, 10.1038/ejhg.2014.44 · DOI
- Kruizinga, 2014, Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations, Endocr. Relat. Cancer, 21, 63, 10.1530/ERC-13-0308 · DOI
- Lammens, 2011, Compliance with periodic surveillance for Von-Hippel-Lindau disease, Genet. Med., 13, 519, 10.1097/GIM.0b013e3182091a1d · DOI
- Launbjerg, 2017, von Hippel-Lindau development in children and adolescents, Am. J. Med. Genet., 173, 2381, 10.1002/ajmg.a.38324 · doi:10.1002/ajmg.a.38324
- Lonser, 2014, Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease, J. Neurosurg., 120, 1055, 10.3171/2014.1.JNS131431 · DOI · Paper page
- Lonser, 2003, von Hippel-Lindau disease, Lancet, 361, 2059, 10.1016/S0140-6736(03)13643-4 · DOI · Paper page
- Maddock, 1996, A genetic register for von Hippel-Lindau disease, J. Med. Genet., 33, 120, 10.1136/jmg.33.2.120 · DOI · Paper page
- Maher, 1991, Von Hippel-Lindau disease: a genetic study, J. Med. Genet., 28, 443, 10.1136/jmg.28.7.443 · DOI · Paper page
- Maher, 2011, von Hippel-Lindau disease: a clinical and scientific review, Eur. J. Hum. Genet., 19, 617, 10.1038/ejhg.2010.175 · DOI · Paper page
- Maranchie, 2004, Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location, Hum. Mutat., 23, 40, 10.1002/humu.10302 · DOI
- McNeill, 2009, Genotype-phenotype correlations in VHL exon deletions, Am. J. Med. Genet., 149A, 2147, 10.1002/ajmg.a.33023 · DOI
- Melmon, 1964, LINDAU'S disease. Review of the literature and study of a large kindred, Am. J. Med., 36, 595, 10.1016/0002-9343(64)90107-X · doi:10.1016/0002-9343(64)90107-x
- Mehta, 2021, Endolymphatic sac tumor screening and diagnosis in von Hippel-lindau disease: a consensus statement, J Neurol Surg B
- Moller, 1930, Familiær Angiomatosis retinae et cerebelli -Lindau's Sygdom, Ugeskr Laeger, 92, 379
- Moller, 1952, Another family with von Hippel-Lindau's disease, Acta Ophthalmol., 30, 10.1111/j.1755-3768.1952.tb07650.x · doi:10.1111/j.1755-3768.1952.tb07650.x
- Neumann, 1991, Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus, Lancet, 337, 1052, 10.1016/0140-6736(91)91705-Y · DOI · Paper page
- Nordstrom-O'Brien, 2010, Genetic analysis of von Hippel-Lindau disease, Hum. Mutat., 31, 521
- Pavel, 2016, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site, Neuroendocrinology, 103, 172, 10.1159/000443167 · DOI · Paper page
- Poulsen, 2010, Surveillance in von Hippel-Lindau disease (vHL), Clin. Genet., 77, 49, 10.1111/j.1399-0004.2009.01281.x · doi:10.1111/j.1399-0004.2009.01281.x
- Poulsen, 2011, von Hippel-Lindau disease: surveillance strategy for endolymphatic sac tumors, Genet. Med., 13, 1032, 10.1097/GIM.0b013e31822beab1 · doi:10.1097/gim.0b013e31822beab1
- Rasmussen, 2010, Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease, BMC Med. Genet., 11, 4, 10.1186/1471-2350-11-4 · doi:10.1186/1471-2350-11-4
- Rednam, 2017, Von hippel-lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood, Clin. Cancer Res., 23, e68, 10.1158/1078-0432.CCR-17-0547 · DOI · Paper page
- Salama, 2019, Comprehensive characterization of a Canadian cohort of von Hippel-lindau disease patients, Clin. Genet., 10.1111/cge.13613 · DOI
- Sgambati, 2000, Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents, Am. J. Hum. Genet., 66, 84, 10.1086/302726 · DOI · Paper page
- Singh, 2001, Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with von Hippel-Lindau disease, Ophthalmology, 108, 1907, 10.1016/S0161-6420(01)00758-8 · doi:10.1016/s0161-6420(01)00758-8
- Wang, 2018, Risk factors for survival in patients with von Hippel-Lindau disease, J. Med. Genet., 55, 322, 10.1136/jmedgenet-2017-104995 · doi:10.1136/jmedgenet-2017-104995
- Wang, 2017, Shorter telomere length increases age-related tumor risks in von Hippel-Lindau disease patients, Cancer Med., 6, 2131, 10.1002/cam4.1134 · DOI
- Wiley, 2019, Management of retinal hemangioblastoma IN VON hippel-lindau disease, Retina, 39, 2254, 10.1097/IAE.0000000000002572 · DOI
- Wind, 2011, Management of von Hippel-Lindau disease-associated CNS lesions, Expert Rev. Neurother., 11, 1433, 10.1586/ern.11.124 · doi:10.1586/ern.11.124
- Ye, 2012, Effect of pregnancy on hemangioblastoma development and progression in von Hippel-Lindau disease, J. Neurosurg., 117, 818, 10.3171/2012.7.JNS12367 · doi:10.3171/2012.7.jns12367
- Yoon, 2022, Genetic counseling and long-term surveillance using a multidisciplinary approach in von Hippel-lindau disease, Ann. Lab. Med., 42, 352, 10.3343/alm.2022.42.3.352 · DOI
- Yu, 2019, Allosteric inhibition of HIF-2alpha as a novel therapy for clear cell renal cell carcinoma, Drug Discov. Today, 24, 2332, 10.1016/j.drudis.2019.09.008 · DOI
- Zhang, 2021, Clinical characteristics and risk factors for survival in affected offspring of von Hippel-Lindau disease patients, J. Med. Genet.
Metadata
- Authors
- Louise M Binderup, M., Smerdel, M., Borgwadt, L., Beck Nielsen, S. S., Madsen, M. G., Møller, H. U., Kiilgaard, J. F., Friis-Hansen, L., Harbud, V., Cortnum, S., Owen, H., Gimsing, S., Friis Juhl, H. A., Munthe, S., Geilswijk, M., Rasmussen, Å. K., Møldrup, U., Graumann, O., Donskov, F., Grønbæk, H., Stausbøl-Grøn, B., Schaffalitzky de Muckadell, O., Knigge, U., Dam, G., Wadt, K. A., Bøgeskov, L., Bagi, P., Lund, L., Stochholm, K., Ousager, L. B., & Sunde, L.
- Venue
- European Journal of Medical Genetics
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 65
- Issue
- 8
- Pages
- 104538
- ISSN
- 1769-7212
- Cited by
- 120
- References
- 6
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.